S U M M A R Y S E T T I N G :
Over 150 potentially pathogenic non-tuberculous mycobacteria (NTM) species have been described, posing an onerous challenge for clinical laboratory diagnosis. O B J E C T I V E : To evaluate different approaches for the identification of 40 clinically relevant NTM isolates whose species were not reliably identified using our routine diagnostic workflow comprising phenotypic tests and hsp65 polymerase chain reaction restriction analysis. D E S I G N : We used 1) sequencing analysis of four conserved gene targets: 16S rRNA, rpoB, hsp65 and sodA; 2) two commercial reverse hybridisation assays; and 3) protein analysis using matrix-assisted laser desorption/ionisation time of flight mass spectrometry (MALDI-TOF MS). R E S U LT S : Combined, but not individual, sequence analysis allowed reliable species identification for 30/ 40 (75%) isolates, including species previously unknown to be circulating in Argentina. Commercial kits outperformed our routine identification in only 5/35 isolates, and misclassified many more. MALDI-TOF MS accurately identified species in 22/36 (61%) isolates and did not misidentify any. C O N C L U S I O N S : Commercial kits did not resolve the problem of species of NTM isolates that elude identification. Combined DNA sequence analysis was the approach of choice. MALDI-TOF MS shows promise as a powerful, rapid and accessible tool for the rapid identification of clinically relevant NTM in the diagnostic laboratory, and its accuracy can be maximised by building up a customised NTM spectrum database. K E Y W O R D S : mycobacteriosis; DNA sequence analysis; matrix-assisted laser desorption-ionization mass spectrometry (MALDI-TOF MS); DNA probes; nucleic acid hybridisation CURRENT GENOMIC APPROACHES ALLOW increasing numbers of non-tuberculous mycobacteria (NTM) taxa to be identified, many of which are genetically close to each other, composing intricate groups or complexes. Over 150 mycobacterial species have been described that are potential human pathogens, posing a significant challenge for clinical laboratory diagnosis. 1,2 NTM infection, known as mycobacteriosis, is often associated with immunosuppression, comorbidity, or use of improperly sterilised substances or equipment in surgical and cosmetic procedures. 3, 4 Given their environmental pervasiveness, occasional NTM isolation from nonsterile clinical specimens such as sputum samples does not allow us to presume the presence of mycobacteriosis. A comprehensive case-by-case approach is required, including clinical, imaging and microbiological assessment, to define the NTM responsible for a given medical condition. 5, 6 Accurate identification of NTM helps clinical management and is essential for assessing species distribution in a given epidemiological setting and elucidating the role of NTM in human disease. Most mycobacterial identification methods are now based on nucleic acid techniques. Sequencing of conserved genetic regions is the gold standard; widely used targets are 16S rDNA, hsp65 and 16S-23S internal transcribed spacer (ITS). Other targets have also been proposed, such as rpoB, gyrA/B, dnaJ, sodA, secA1 and recA. 7, 8 Due to the close links among mycobacteria, sequencing of a single DNA target does not always guarantee species discrimination. 2 Published data on the efficiency of individual targets are still limited and their performance has not been fully compared. [9] [10] [11] Commercial DNA hybridisation assays are available; however, these vary in accuracy and do not individually cover the whole spectrum of clinically relevant mycobacteria. [12] [13] [14] Matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry (MALDI-TOF MS) has recently been introduced into clinical laboratories for microbial identification based on protein spectra. 15 This technology offers advantages for routine diagnostics, such as versatility, application in multiple pathogens, low cost of consumables and simple, rapid working protocols. 16 Published data on the prevalence of NTM in Argentina are scarce. [17] [18] [19] According to our laboratory records, mycobacterioses represent~1.3% of cases notified as having tuberculosis (TB). Following global trends, slowly growing mycobacteria (SGM) account for~75% of diseases caused by NTM in humans in Argentina; members of the Mycobacterium avium complex and M. kansasii are the predominant species. Among rapidly growing mycobacteria (RGM), those most frequently associated with disease in humans are members of the M. chelonae-abscessus group and the M. fortuitum complex. Our laboratory (Instituto Nacional de Enfermedades InfecciosasAdministración Nacional de Laboratorios e Institutos de Salud [ANLIS]) acts as the reference laboratory for microbiological diagnosis of human TB and mycobacteriosis in Argentina. We perform mycobacterial identification based on phenotypic tests and polymerase chain reaction-restriction analysis (PRA) using the hsp65 gene as target. 20, 21 The former is time-consuming and insufficiently accurate, while the latter has limitations such as different species sharing identical restriction profiles. Approximately 20% of NTM isolates do not receive species assignation, and unidentified clinically relevant isolates are submitted for sequencing elsewhere.
The present study aimed to seek the best single or combined approach for the identification of a set of NTM clinical isolates whose species could not be unequivocally resolved in our laboratory. To this end, we used 1) sequencing of four genes, 16S rDNA, rpoB, hsp65 and sodA; 2) two rapid commercial kits, Vircell Speed-Oligo w Mycobacteria (Vircell, Granada, Spain) and Hain GenoType Mycobacterium CM/AS (Hain Lifescience, Nehren, Germany); and 3) protein spectrum analysis using MALDI-TOF MS.
MATERIALS AND METHODS
Routine identification and isolate selection Of~1000 mycobacterial clinical isolates referred annually to our laboratory,~200 are NTM. Phenotypic identification includes growth rate, growth temperature, growth in 5% sodium chloride Löwenstein-Jensen (LJ) medium, pigmentation and colony morphology, and the following biochemical tests: catalase (room temperature and 688C), nitrate reductase, Tween 80 hydrolysis, arylsulfatase, urease, b-glucosidase, b-galactosidase, pyrazinamidase and iron uptake. PRA is based on polymerase chain reaction (PCR) amplification of a 441 base pair (bp) hsp65 segment, followed by digestion using BstEII and HaeIII. 20, 21 Restriction patterns are compared on PRAsite (http://app.chuv.ch/prasite/index.html).
We selected 40 NTM isolates representative of ambiguous phenotypic and/or PRA patterns, obtained from 39 clinically proven or highly suspicious cases of mycobacteriosis in 2002-2014. Culture, routine identification and the MALDI-TOF MS assay were performed at the Instituto Nacional de Enfermedades Infecciosas, ANLIS. Reverse hybridisation assays and gene sequencing were performed at Ghent University, Ghent, Belgium. Ethics committee approval and informed consent were not required because the work was retrospective and data were anonymised.
Sequencing DNA was obtained by boiling lysis of bacilli freshly grown on LJ slants. Conventional PCRs were performed for partial amplification of 16S rRNA, rpoB, hsp65 and sodA genes using primers depicted in Appendix Table A. 1.* 9, 20, 22, 23 Identical primers were used for sequencing PCR (BigDye Terminator Sequencing Kit, Applied Biosystems, Foster City, CA, USA), except for the 16S rRNA gene, in which case internal reverse primer BKL1 was used. Purified products (BigDye XTerminator kit, Applied Biosystems) were sequenced using the ABI Prism 3130 XL Genetic Analyzer (Applied Biosystems). Sequence assembly was performed with BioNumerics v. 7.0 (Applied Maths, Sint-Martens-Latem, Belgium). Targets were subjected to BLAST (Basic Local Alignment Search Tool) recognition in the following databases: National Center for Biotechnology Information (http://blast.ncbi.nlm.nih.gov/Blast.cgi), EzBioCloud (http://www.ezbiocloud.net/), and Mycobacterium 65 Kilodalton Heat Shock Protein Gene BLAST (http:// hsp65blast.phsa.ca/blast/blast.html). To assign species, 799.7% similarity to type strain sequences was required for 16S rRNA, 797% for rpoB and 799% for both hsp65 and sodA. 9, 23, 24 Reverse hybridisation assays Speed-Oligo Mycobacteria (Vircell) consists of targeting 16S rDNA and the internal transcribed spacer in a double PCR, followed by reverse hybridisation with specific probes immobilised onto a dipstick and colour detection. The test reliably identifies Mycobacterium genus, M. tuberculosis complex and 13 NTM to species or complex level. 12, 13 GenoType w Mycobacterium CM/AS (Hain Lifescience), also based on DNA strip technology, uses 23S RNA as target. The procedure comprises multiplex amplification using biotinylated primers, reverse hybridisation and colour detection. The CM (common mycobacteria) component allows identification of M. tuberculosis complex and 13 NTM species or groups frequently isolated from clinical specimens. The AS (additional species) component allows identification of 16 less common NTM. 14 All assays were performed following the manufacturers' instructions.
MALDI-TOF MS
Proteins were extracted as described, with minor modifications. 15 A loopful of bacilli freshly grown onto LJ slants was suspended in 0.5% Tween 80 distilled water, inactivated, and rinsed in 70% ethanol. The pellet was re-suspended in 100% formic acid and 0.1 mm zirconia-silica beads. After adding 100% acetonitrile, vortexing, and centrifuging, the supernatants were transferred into fresh tubes. Next, 1 ll was pipetted onto each spot on the MALDI-TOF plate and allowed to dry; then 1 ll of MALDI-TOF matrix was added and allowed to dry again. Spectra were analysed against the Bruker database v. 3.1 (Biotyper System; Bruker BioSciences Corporation, Billerica, MA, USA). Manufacturers recommend scores 72.0 for optimal identification at the species level. On the basis of our experience with mycobacterial identification using MALDI-TOF MS, and that of others, we considered an isolate achieving a score 71.7 to have been reliably identified, provided that the result was concordant with results of phenotypic tests and hsp65 PRA. 25, 26 
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Sample characteristics and routine identification
Appendix Table A 
Gene sequencing analysis
BLAST results are presented in Appendix Table A.4. Sequencing PCR failed to amplify one isolate in 16S rDNA, one in rpoB and three in sodA. As not all isolates attained the required proportion of similarities to type strain sequences, we asked for concordant results of at least two genes for species identification. Concordant species assignation of at least two gene sequences was achieved for 30/40 (75%) isolates, almost invariably involving 16S rDNA and rpoB, most hsp65, and less frequently all four gene targets. Only 11/37 (29.7%) isolates successfully sequenced for sodA were correctly identified to the species level. This gene was virtually unable to correctly identify M. senegalense, M. lentiflavum, M. triplex and M. colombiense. M. senegalense and M. lentiflavum, respectively, were the RGM and SGM species most frequently identified. M. triplex was initially identified using PRA in two sputum specimens obtained from the same patient 2 years apart and confirmed using combined gene analysis.
Reverse hybridisation assays A total of 35/40 isolates were available for testing using both commercial kits. Speed-Oligo Mycobacteria identified 19 isolates up to the genus level and assigned mycobacterial species to 16. Only 4/16 were accurately classified according to consensus sequencing of two or more gene targets. GenoType Mycobacterium CM allowed species identification in 32 isolates, only five of which were correctly assigned according to consensus sequencing. GenoType AS contributed to the correct identification of six additional SGM isolates, and none of the RGM isolates. Overall, GenoType Mycobacterium CM/AS outperformed our identification routine in five isolates.
MALDI-TOF MS
Of 36 NTM isolates analysed, 22 (61%) were correctly identified, while 14 did not attain a reliable MALDI-TOF MS score. Using consensus sequence analysis, five isolates that were determined to be M. senegalense, a species not present in the Bruker database v. 3.1, were initially identified as the M. farcinogenes/M. senegalense group by MALDI-TOF MS. After introducing spectra of three sequencingconfirmed M. senegalense strains into our customised MALDI-TOF MS database, all five M. senegalense isolates in our study were correctly re-classified. MALDI-TOF MS did not discriminate between two pairs of species: M. intracellulare/M. chimaera and M. mucogenicum/M. phocaicum. The latter pair could not be differentiated using gene sequencing either.
Appendix Tables A. 5 and A.6 show the results of consensus gene sequencing, hybridisation kits and MALDI-TOF MS for RGM and SGM, respectively, against our laboratory initial identification. The 
DISCUSSION
Two commercial rapid assays with proven accuracy and ease of use performed poorly when applied to a set of clinically relevant NTM isolates eluding species assignation in our laboratory workflow. These kits cover a range of species representative of diseaserelated NTM that are globally prevalent. [12] [13] [14] How-ever, the mycobacteria accurately identified by these assays do not represent a diagnostic challenge to our medium-resource laboratory. As previously observed, these kits fail precisely when we challenge them to identify less frequent NTM species. 27 More importantly, they yield a number of erroneous species assignations.
When applied to our set of isolates, 16S rDNA, rpoB and hsp65 were often in agreement in assigning species for both RGM and SGM. In line with previous reports, sodA sequence analysis did not add much certainty. 2, 9 This is partially related to the fact that sodA sequences are not available for a number of NTM species in public databases (http://blast.ncbi. nlm.nih.gov/Blast.cgi). We failed to extend sequence analysis to other gene targets, in particular to ITS, due to difficulties in amplification (data not shown). A similar amplification failure might explain the poor performance of Speed-Oligo Mycobacteria in our isolates, as the assay is partly based on ITS.
Until whole-genome sequencing analysis becomes widely available for microbial identification, consensus sequencing results of at least two, and ideally three, conserved genetic regions seems to be a reliable approach for species determination in diagnostic settings such as ours. This criterion is intended not to yield strict taxonomic classifications, but to provide pragmatic, definite identification of clinical NTM isolates. It may, nevertheless, fail to distinguish between pairs of closely related species such as M. phocaicum and M. mucogenicum.
Most of the SGM in our study were associated with lung disease and belonged to three large, heterogeneous NTM groups that defy systematisation even today: M. avium complex, M. simiae complex and M. terrae complex. Only M. simiae and M. sherrisii were associated with disseminated disease in our series, associations that were previously recorded as infrequent in Argentina. 28 We were unable to assign a definite species to members of the M. terrae complex even after using combined sequencing analysis. We verified the presence of two SGM species previously unknown to be circulating in Argentina. One is M. colombiense, which we found to be associated with human immunodeficiency virus (HIV) infection; it is likely that this member of the M. avium complex 29 had not been previously reported in our laboratory due to the insufficient resolution of our diagnostic tools. The other is M. triplex, an emerging member of the M. simiae complex, 30 which was identified in two sputum specimens from a single HIV-negative patient with chronic lung disease. This is the only case of M. triplex definitely associated with human disease in our setting. In our PRA database, which contains over 10 000 patterns from Argentina recorded since 2003, only two other M. triplex PRA patterns are recorded, and both were occasional findings.
Our set of RGM isolates were more diverse in mycobacterial species and targeted more patient organs than SGM. Like the SGM, they included species previously unreported in Argentina, such as M. mageritense and M. aubagnense. 31, 32 Four scotochromogens in this group were tenaciously refractory to identification by combined gene sequencing, even to the complex level. We hypothesise that these strains represent as yet unrecognised species which would have remained unidentified independently of the approach used. More than a third of the RGM in our study were involved in surgical complications, including M. senegalense, members of the M. smegmatis group, and the above-mentioned unclassified scotochromogens, which underlines the fact that NTM involved in surgical wound infections are not restricted to members of the M. abscessus complex. A remarkable finding is the isolation of M. vanbaalenii, an RGM closely related to M. vaccae, 33 in a patient with a rare recurrent meningeal syndrome. Regarding the involvement of M. peregrinum in human disease, in line with other authors, we were able to reliably assess its aetiological role in our pulmonary case but not in the case of urinary infection. 34 We did not detect any geographic association of the species identified in the study.
We have adapted the MALDI-TOF MS protocol to extract proteins directly from LJ slants to reduce costs and, most importantly, to detract as little as possible from our laboratory routine. The Bruker database v. 3.1, against which we analysed our spectra, is still deficient in terms of both the number of NTM species represented and the number of spectra per species. After incorporating M. senegalense into our customised spectra database, MALDI-TOF MS successfully identified species for .60% of the isolates in our study, and, most importantly, this method did not lead to any misclassification. This is a remarkable performance for a particularly difficult-to-type set of isolates, second only to combined sequencing (Figure) . Furthermore, MALDI-TOF MS analysis is open to continuous improvement. We are currently maximising its accuracy by building up a customised NTM database. Upon further examination, we are considering incorporating this tool into our diagnostic workflow. We envisage a modified algorithm to achieve a more accurate identification of NTM in Argentina. First, it will analyse PRA patterns and phenotypic characteristics such as pigmentation and growth rate. MALDI-TOF MS will then be used. Finally, in case of incongruent or undefined results, we will submit the isolate to 16S rDNA and rpoB sequencing. The increasing availability of NTM whole genome sequences will probably allow the selection of further conserved DNA regions suitable for species identification in the near future. If MALDI-TOF MS databases are expanded, requirements for gene analysis will eventually decrease in clinical laboratories, allowing faster and more accurate NTM species identification.
In conclusion, commercial DNA kits were not valid options for resolving the problem of specimens that elude NTM species identification in Argentina. Multiple, but not single, gene analysis is the approach of choice; however, this does not guarantee identification to the species level in every case. The systematic use of MALDI-TOF MS would allow swift and reliable species identification of clinically relevant NTM in the diagnostic laboratory, thereby substantially reducing the number of isolates requiring multiple gene sequencing or whole genome sequencing for species assessment. C O N C L U S I O N E S: Las pruebas comerciales no resolvieron la asignación de especies de NTM difíciles de identificar. El aná lisis combinado de secuencias continúa siendo el método de elección. MALDI-TOF MS emerge como una herramienta poderosa y accesible con potencial para la identificación rá pida de NTM de interés clínico en el laboratorio diagnóstico. Su precisión puede ser maximizada mediante la construcción de bases de datos personalizadas de espectros de especies de NTM.
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